Olymvax

Founded in 2009, Olymvax Biopharmaceuticals Inc. is a national high-tech enterprise, focusing on the R&D, production and marketing of human-use vaccine. Its registered capital is 205.68 million CNY. The factory covers an area of 5.4 acres, with m2 (828,800 square feet) in the construction plan and square meters already finished. Olymvax was listed in the national equities exchange anf quotations in September, 2015 (Stock code: 833577). Adhering to the business philosophy of "strengthening process management, committing to continuous improvement and pursuing the highest quality", Olymvax aims to be an “internationally well-known and domestically leading” vaccine supplier. As for the construction and management of the production facility, Olymvax not only conforming to Chinese GMP 2010, but also referring to Euro-American advanced criteria, preparing for the products’ worldwide marketing. As for the R&D, Olymvax holds the bi-wheel strategy of “developing novel vaccine, while upgrading traditional vaccine”. By now Olymvax has sucessfully built the cooperation relationships with several worldwide top universities to develop class 1 new vaccines. Through years’ hard working, Olymvax has formed a stair-like product pipeline, that is, a traditional vaccine has been launched, while several innovative vaccines and upgrading vaccines are in the process of good development. Olymvax organized the Children's Day celebration party, themed as “Children's Day, I am Olymvax Little Man”. Olymvax staff and their children gathered together, participated in meaningful scientific experiments.(1) SichuanChengdu 2009 201-500 human vaccineglobally cooperationClass 1 new drugworldwidely S & MR & D platform